NL-OMON20360已完成不适用
A phase I/II feasibility study of the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with poor and very poor-risk AM
HOVO0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Eligibility for registration:
- •- Patients with poor-risk or very poor-risk AML or RAEB with IPSS ¡Ý 1.5 , (see appendix D). During the phase I part only very poor-risk patients will be included
排除标准
- •Eligibility for registration:
- •- History of active malignancy during the past 2 years with the exception of basal carcinoma of the skin or carcinoma ¡°in situ¡± of the cervix or breast
研究者
相似试验
招募中
不适用
A phase lb feasibility study of the combination of panobinostat and midostaurin in recipients of allogeneic stem cell transplantation with Flt3-ITD AMAcute Myeloid LeukemiaNL-OMON29431HOVON Data Center30
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of combination chemotherapy of panobinostat and decitabine, given after donor stem cell transplantation in patients with (very) poor risk AM(very) poor risk AML or RAEB with IPSS = 1.5MedDRA version: 18.0Level: LLTClassification code 10024329Term: LeukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003344-74-BEHOVON Foundation100
进行中（未招募）
1 期
A study about the treatment of patients with a specific type of AML with a combination of panobinostat and midostaurin during 1 year after allogeneic stem cell transplantation .EUCTR2017-002335-42-NLHOVON Foundation40
已完成
不适用
Therapeutic Yoga and Resistance Exercise for Lung CancerLung CancerNCT03084692University of Alberta23
进行中（未招募）
1 期
A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma.EUCTR2017-002605-35-BEHOVON Foundation109